Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01390571
Other study ID # CDR0000702605
Secondary ID CRUK-CR0901-11EU
Status Completed
Phase Phase 1
First received July 7, 2011
Last updated February 1, 2018
Start date July 2011
Est. completion date June 20, 2017

Study information

Verified date February 2018
Source Cancer Research UK
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Olaparib may help temozolomide kill more tumor cells by making tumor cells more sensitive to the drug.

PURPOSE: This phase I trial is studying the side effects and best dose of olaparib and temozolomide in treating patients with relapsed glioblastoma.


Description:

OBJECTIVES:

Primary

- To determine whether olaparib crosses the blood-brain barrier (BBB) and achieves tumor penetration in patients with relapsed glioblastoma. (Stage 1)

- To determine the safety and tolerability of the combination of olaparib and temozolomide in patients with relapsed glioblastoma. (Stage 2)

Secondary

- To assess BBB disruption and BBB permeability in patients with relapsed glioblastoma. (Stage 1 and stage 2 maximum-tolerated dose [MTD] expansion cohort)

- To assess the possible anti-tumor activity of the combination of olaparib and temozolomide in patients with relapsed glioblastoma. (Stage 2)

Tertiary

- To assess biological markers as possible predictors of olaparib efficacy in patients with glioblastoma.

- To optimize techniques for measuring DNA damage responses to PARP inhibition in tumor tissue.

- To determine plasma concentration of olaparib at the time of surgery in patients with glioblastoma.

- To evaluate the PARP inhibition at the time of surgery in peripheral blood mononuclear cells (PBMCs).

OUTLINE: This is a multicenter, dose-escalation study.

- Stage 1: Patients receive fixed-dose oral olaparib twice daily for 3 days prior to resection and then receive a dose of oral olaparib on the morning of the resection. After the surgical resection, patient receive standard of care treatment. Patients undergo dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) scans to assess the disruption and permeability of the blood-brain barrier (BBB).

Stage 1 is complete and it was proven that olaparib can cross the BBB and achieve tumour penetration in glioblastoma patients.

- Stage 2: Patients receive escalating doses of oral olaparib once or twice daily for 3 days prior to resection and then receive a dose of oral olaparib on the morning of the resection. After recovery from surgery, patients receive oral olaparib once or twice daily and oral temozolomide once daily on days 1-42. Treatment repeats every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients may receive 3 additional courses of treatment in the absence of disease progression.

Once the maximum tolerated dose (MTD) is established, 10 more patients are treated at the MTD as stage 2 MTD expansion cohort. These patients also undergo DCE-MRI and DWI scans.

All patients undergo blood collection periodically for pharmacokinetic and pharmacodynamic studies.

After completion of study treatment, patients are followed up for 28 days and then monthly until resolution of study drug-related adverse events.

Peer Reviewed and Funded or Endorsed by Cancer Research UK.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date June 20, 2017
Est. primary completion date June 20, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed grade IV glioblastoma

- Radiological diagnosis of recurrent or progressive disease according to Response Assessment in Neuro-Oncology Working Group (RANO) criteria, which is suitable for palliative resection

- Must have an adequate amount of tumor tissue available

- Previously received first-line treatment with radical radiotherapy, or chemoradiation followed by adjuvant chemotherapy

- No prior chemotherapy for recurrent disease

PATIENT CHARACTERISTICS:

- WHO performance status 0-2

- Life expectancy > 12 weeks

- Hemoglobin = 10.0 g/dL

- Absolute neutrophil count = 1.5 x 10^9/L

- Platelet count = 100 x 10^9/L

- Serum bilirubin = 1.5 times upper limit of normal (ULN)

- ALT or AST = 2.5 times ULN

- Calculated creatinine clearance = 50 mL/min OR isotope clearance measurement = 50 mL/min (uncorrected)

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use one (male) or two (female) highly effective forms of contraception 4 weeks prior to, during, and for 6 months after completion of study therapy

- Able to swallow and retain oral medications

- Not at high medical risk due to non-malignant systemic disease, including active uncontrolled infection

- No known hepatitis B, hepatitis C, or HIV seropositivity

- No concurrent congestive heart failure, prior history of NYHA class III-IV cardiac disease, prior history of cardiac ischemia, or prior history of cardiac arrhythmia within the past 12 months

- No grand mal seizures occurring = 3 times per week over the past month

- No gastrointestinal disorders likely to interfere with absorption of the study medication

- No known hypersensitivity to any of the components of olaparib

- No known hypersensitivity to temozolomide (TMZ) or any of its components, or to dacarbazine (DTIC) (for patients enrolled in stage 2 study only)

- No known lactose intolerance (for patients enrolled in the stage 2 study only)

- No metal fragments in the eyes (shrapnel or bullet injuries are excluded on the basis of their unsuitability to undergo MRI scans)

- No other condition which, in the Investigator's opinion, would not make the patient a good candidate for the clinical trial

EXCLUSION CRITERIA:

- See Disease Characteristics

- No ongoing toxic manifestations from previous treatments except for alopecia or grade 1 toxicities which, in the opinion of the Investigator and the Drug Development Office (DDO), should not exclude the patient

- At least 12 weeks since prior radiotherapy, endocrine therapy, or immunotherapy

- At least 6 weeks since prior major surgery

- At least 4 weeks since prior chemotherapy

- At least 4 weeks since prior immunizations with live vaccines (or expected to receive vaccines during the trial and up to at least 6 months after receiving last study treatment), including BCG and yellow fever vaccines

- No prior PARP inhibitors, including olaparib

- No prior major thoracic or abdominal surgery from which the patient has not yet recovered

- No prior heart surgery

- No pacemakers

- No change to systemic steroids dose within 5 days prior to enrollment (i.e., must be on a stable dose at time of enrollment and remain on a stable dose throughout the treatment period)

- No herbal supplements and/or ingestion of foods known to modulate CYP3A4 enzyme activity from time entered on screening period until 28 days after the last dose of study medication

- No concurrent drugs known to be potent inducers of CYP3A4, including phenytoin, carbamazepine, phenobarbital, rifampicin, rifapentine, rifabutin, nevirapine, modafinil, or St. John wort (wash-out period for phenobarbital is 5 weeks, 3 weeks for all others)

- No concurrent drugs known to be potent inhibitors of CYP3A4, including ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, telithromycin, clarithromycin, or nelfinavir (wash-out period is 1 week)

- No concurrent or planned participation in another interventional clinical study

- Participation in an observational study is acceptable

- No concurrent warfarin (patients requiring anticoagulation should be given subcutaneous low molecular weight heparin)

- No other concurrent anticancer therapy (including radiotherapy) or investigational drugs

- No blood transfusions within 4 weeks prior to study start of features suggestive of myelodysplasia or AML

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
olaparib

temozolomide

Genetic:
gene expression analysis

protein expression analysis

Other:
laboratory biomarker analysis

pharmacological study

Procedure:
diffusion-weighted magnetic resonance imaging

dynamic contrast-enhanced magnetic resonance imaging

therapeutic conventional surgery


Locations

Country Name City State
United Kingdom Queen Elizabeth Hospital Birmingham
United Kingdom Bristol Haematology and Oncology Centre Bristol England
United Kingdom Addenbrooke's Hospital Cambridge England
United Kingdom Western General Hospital Edinburgh
United Kingdom Beatson West of Scotland Cancer Centre Glasgow Scotland
United Kingdom Christie Hospital Manchester England
United Kingdom Royal Marsden Hospital Sutton England

Sponsors (1)

Lead Sponsor Collaborator
Cancer Research UK

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Gene copy number analysis of DNA repair genes
Other Quantification of DNA repair gene expression
Other Measurement of methylation of the MGMT promoter gene by bisulfite modification of DNA and pyrosequencing
Other Measurement of microsatellite instability by Multiplex PCR
Other Measurement of mismatch repair (MMR) gene expression by quantitative real time polymerase chain reaction (QRT-PCR) analysis
Other Measurement of phosphatase and tensin homolog (PTEN) protein and gene expression
Other Quantification of global DNA strand breaks in tumour tissue by Immunostaining for ?H2AX
Other Measurement of Rad51 foci and nuclear staining intensity as markers of homologous recombination (HR) repair activity
Other Plasma levels of olaparib measured by LC-MS
Other PARP inhibition measured by validated assays
Other Detection of olaparib in tumour margin tissue using LC-MS
Primary Detection of olaparib in tumor tissue using liquid chromatography mass spectrometry (LC-MS) seen in at least 1 out of the 6 patients treated in stage 1 of the study
Primary Maximum-tolerated dose of olaparib in combination with temozolomide (stage 2)
Primary Toxicity profile and dose-limiting toxicity as assessed by NCI CTCAE Version 4.02 (stage 2)
Secondary Measurement of blood-brain barrier (BBB) disruption and permeability biomarkers by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) (stage 1 and stage 2 MTD expansion cohort)
Secondary Progression-free survival at 6 months post-surgery as assessed by the Response Assessment in Neuro-Oncology Working Group (RANO) criteria from conventional MRI and clinical assessment (stage 2)
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Completed NCT00003484 - Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Phase 1
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1